DMSO-induced changes in the procoagulant and fibrinolytic activity of B16 melanoma cells: influence on lung colony formation. 1988

B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
Istituto di Recerche Farmacologiche Mario Negri, Milano, Italy.

In this study DMSO (dimethylsulphoxide) was used as a tool to test the significance of in vitro modifications of procoagulant and fibrinolytic activity of tumor cells for their in vivo metastatic ability. B16 melanoma cells were chosen as the experimental model. After four days' treatment DMSO increased both the procoagulant and fibrinolytic (plasminogen activator) activity of B16 melanoma cells in a dose-related manner. DMSO treated cells showed significantly greater lung colonizing ability than untreated cells. Our results indicate that DMSO treatment in vitro can modulate procoagulant and fibrinolytic activity and the metastatic ability of B16 melanoma cells; however a direct causal relationship between these in vitro and in vivo effects remains to be established.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D004121 Dimethyl Sulfoxide A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation. DMSO,Dimethyl Sulphoxide,Dimethylsulfoxide,Dimethylsulphinyl,Dimethylsulphoxide,Dimexide,Rheumabene,Rimso,Rimso 100,Rimso-50,Sclerosol,Sulfinylbis(methane),Rimso 50,Rimso50,Sulfoxide, Dimethyl,Sulphoxide, Dimethyl
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
January 1992, In vivo (Athens, Greece),
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
April 1975, International journal of radiation biology and related studies in physics, chemistry, and medicine,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
February 1992, Chinese medical journal,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
June 1986, International journal of cancer,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
September 1995, The Journal of clinical investigation,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
January 1989, Pharmacological research,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
February 1983, Cancer research,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
January 1992, In vivo (Athens, Greece),
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
April 1986, European journal of cancer & clinical oncology,
B Casali, and M G Lampugnani, and M Riganti, and A Niewiarowska, and G Alessio, and L Mussoni, and N Semeraro, and M B Donati
January 2014, Evidence-based complementary and alternative medicine : eCAM,
Copied contents to your clipboard!